Emile Nuwaysir last month joined Cambridge, MA-based BlueRock Therapeutics as chief executive, according to his LinkedIn profile. BlueRock is developing stem cell therapies to repair heart muscle in patients who have had a heart attack. The startup raised $225 million from investors in December.
Previously, Nuwaysir was president and chief operating officer of Madison, WI-based Cellular Dynamics International (CDI). That company is a developer of induced pluripotent stem cells, which can be differentiated into any type of cell found in the human body. Nuwaysir had also served as president of Opsis Therapeutics, a CDI spinoff focused on developing medicines to treat retina diseases. While he is now based in the Boston area, Nuwaysir remains involved with another Wisconsin company, Invenra, says head of alliance management Kimberly Kaufman. Invenra, which Nuwaysir co-founded in 2011, develops therapeutic monoclonal antibodies using cell-free protein expression.
